Abstract

The Effects of Paclitaxel and Metformin and Combined Treatments on TLR Signaling Pathway on MDA-MB-231 Breast Cancer Cell Lines †

Melike Ozgul 1, Elgin Turkoz Uluer 1,*, Tuna Onal 1, Damla Akogullari 1, Kemal Ozbilgin 1 and Sevinc Inan 2

1 Faculty of Medicine, Department of Histology & Embryology, Manisa Celal Bayar University, Manisa 45047, Turkey
2 Faculty of Medicine, Department of Histology & Embryology, Izmir University of Economics, Izmir 35040, Turkey
* Correspondence: drelginturkoz@gmail.com; Tel.: +90-0505-3698-978
† Presented at the 2nd International Conference on Natural Products for Cancer Prevention and Therapy, Kayseri, Turkey, 8–11 November 2017.

Abstract: The aim of this study was to determine the effects of Paclitaxel, Metformin and combined treatments on human breast cancer cell line MDA-MB-231 via TLR signaling pathway using immunocytochemical technique. MDA-MB-231 breast cancer cells were cultured in RPMI-1640 medium containing 10% FBS, 1% L-glutamine and 1% penicillin/streptomycin. Anti-TLR2, anti-TLR4, anti-MyD88, anti-NFkB, anti-IL-6 and anti-ERK primary antibodies were used for indirect immunohistochemistry after 24 h administrations of Paclitaxel, Metformin and combination of them. The mean values of the staining intensities (mild, moderate, strong and very strong) and percentage of positively stained cells were calculated using H-Score. The results showed that the immunoreactivities of TLR-2, TLR-4, MyD88, NFKB and ERK is increased after the drug treatments while the immunoreactivity of IL-6 has not changed between control and treated groups. To conclude that paclitaxel, metformin and combined therapies on breast cancer cells caused the activation of the TLR-MyD88-ERK signaling pathway which mediates tumor growth and progression, metastasis and drug resistance.

Keywords: breast cancer cell line; paclitaxel; metformin; TLR

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).